Hiroshi Nomura
Chief Executive Officer bij SUMITOMO PHARMA CO., LTD.
Profiel
Momenteel bekleedt Hiroshi Nomura de functie van President & Representative Director bij Sumitomo Dainippon Pharma Co, Ltd. Hij zit ook in de raad van bestuur van Sunovion Pharmaceuticals, Inc., Myovant Sciences Ltd. en Sumitovant Biopharma, Inc. Hij behaalde een bachelorgraad aan de Universiteit van Tokio.
Actieve functies van Hiroshi Nomura
| Bedrijven | Functie | Begin |
|---|---|---|
| SUMITOMO PHARMA CO., LTD. | Chief Executive Officer | 01-04-2018 |
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Director/Board Member | - |
Tolero Pharmaceuticals, Inc.
 Tolero Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT. | Director/Board Member | - |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The private company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Director/Board Member | - |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Director/Board Member | - |
Eerdere bekende functies van Hiroshi Nomura
| Bedrijven | Functie | Einde |
|---|---|---|
| ROIVANT SCIENCES LTD. | Director/Board Member | 31-08-2023 |
| MYOVANT SCIENCES LTD. | Director/Board Member | 22-10-2022 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Director of Finance/CFO | 01-04-2014 |
Opleiding van Hiroshi Nomura
| University of Tokyo | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| ROIVANT SCIENCES LTD. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The private company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Tolero Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Health Technology |
